The global biopharmaceutical landscape is undergoing a period of unprecedented capital intensity and structural evolution. At the vanguard of this shift is FUJIFILM Biotechnologies, a Contract Development and Manufacturing Organization (CDMO) currently orchestrating a $7 billion global expansion. As the industry grapples with the complexities of scaling life-saving therapies—ranging from monoclonal antibodies to advanced cell and gene treatments—the company is betting that the path to success lies in the marriage of massive physical infrastructure with a radical, decentralized approach to digital operations and human leadership.
Central to this transformation is Maja Herold Pedersen, who ascended to the role of Chief Operating Officer (COO) in September 2025. Her leadership trajectory, which spans from Chief Quality Officer to CTO and now to operations, reflects the changing mandate of the modern biopharmaceutical executive: a move away from rigid, siloed quality control toward an integrated, AI-empowered operational model.
The Strategic Buildout: A $7 Billion Expansion
FUJIFILM Biotechnologies is currently executing one of the most ambitious infrastructure projects in the history of the life sciences sector. The scale of this investment is a direct response to the burgeoning demand for high-capacity, flexible manufacturing that can support diverse therapeutic pipelines.
Key Infrastructure Milestones:
- Holly Springs, North Carolina: The centerpiece of the strategy, this $3.2 billion site serves as a commercial-scale cell culture manufacturing hub. The facility brought its first phase online in September 2025, with a second phase slated for 2028.
- Hillerød, Denmark: The European campus is undergoing a massive augmentation, adding eight 20,000-liter bioreactors and two new downstream processing streams to bolster global capacity.
- Teesside, United Kingdom: In early 2026, the company unveiled the UK’s largest single-use CDMO facility, specifically designed for rapid clinical and commercial production.
- Madison, Wisconsin: Subsidiary FUJIFILM Cellular Dynamics opened a new iPSC (induced pluripotent stem cell) manufacturing headquarters in May 2026, backed by a $200 million investment designed to quadruple cell-production capacity.
These sites are not merely disparate factories; they are connected via "kojoX," a modular bioproduction ecosystem. By standardizing equipment, quality systems, and processes across global borders, the company aims to enable the seamless transfer of validated drug-substance processes, significantly compressing the time required for regulatory approval and market entry.
The Quality-to-Operations Pipeline
Maja Herold Pedersen’s rise to COO is illustrative of a broader trend: the elevation of "quality" from a back-office compliance function to a core strategic engine of operations. Reflecting on her transition, Pedersen notes that her background in quality never restricted her vision.
"I’ve never been a quality-function-only leader," Pedersen says. "I’ve always looked at the whole picture of how we get medicine to patients. It doesn’t matter whether I’m wearing a quality hat or some other hat; we need to make this work for patients in the end."
Her career began not in the sterile, high-tech environments of today, but in the trenches of manufacturing training. Early in her career, she traveled to Mexico to implement quality management systems like TrackWise. This foundational experience in regulatory compliance—paired with direct engagement with patient advocacy groups—forged a leadership philosophy centered on the end-user. For Pedersen, the complexity of modern manufacturing is not a deterrent to speed, but an invitation to innovate.
Industrializing AI: Beyond the Pilot Phase
The most significant friction point in biopharma’s digital transformation is the tension between innovation and regulatory compliance. Many organizations remain stuck in a "pilot purgatory," where AI projects exist only in sandboxed environments. Pedersen is actively dismantling this barrier at FUJIFILM Biotechnologies.
The "GenkiBot" Ecosystem
Recognizing that employees would inevitably turn to unauthorized AI tools if the company did not provide a secure alternative, Pedersen oversaw the development of "GenkiBot"—an in-house, proprietary generative AI platform. Named after the Japanese term for enthusiasm and positivity, GenkiBot operates under a strict security umbrella that protects sensitive intellectual property while democratizing AI access.
The platform is already delivering measurable outcomes in deviation management. By coaching subject matter experts (SMEs) through the analysis of manufacturing deviations, the AI helps identify root causes based on objective data, rather than relying on historical, anecdotal bias. Currently, roughly 50% of deviation-related workflows utilize the tool, with the company aiming for 100% adoption.
Scaling Through "Agentic" Freedom
Pedersen’s approach to AI is intentionally contrarian. Rather than locking down AI tools to prevent error, she argues that the industry must build a wide "funnel" of experimentation. "I’m a big believer that scaling only follows the actual speed if we set it free," she explains.
Her vision involves equipping employees with the ability to "code" their own agents, similar to the way macros transformed the utility of spreadsheets decades ago. While the final, critical GMP (Good Manufacturing Practice) decisions remain reserved for human experts, the foundational work—data gathering, documentation, and process organization—is being handed over to agents. This strategy aims to automate the "tedious" aspects of tech transfer, freeing human talent to focus on high-level problem solving.
The Culture of Empowerment: "9 People Fundamentals"
At the heart of Pedersen’s operational strategy is the "9 People Fundamentals"—a framework designed to balance the extreme complexity of biomanufacturing with the necessity for individual agency.
The Biological Metaphor
Pedersen likens her ideal corporate structure to a biological organism. "We have our brain, and then we have numerous cells out in the body, and they actually work very well individually," she explains. "There’s a brain structure that makes it all flow in one direction, so the cells don’t all go off and do their own thing. But the immediacy of what each individual can do when they’re set free—that’s what we need in the future."
This philosophy is not merely theoretical. It is being codified through the "Leaders for Life" initiative, a leadership development program currently being rolled out across the global organization. The program forces leaders to confront their own biases, reactions, and decision-making styles.
By empowering individuals to make decisions at the point of action, the company aims to reduce the "tedious decision paths" that often plague large-scale, hierarchical pharmaceutical organizations. However, Pedersen is quick to note that this freedom is not a shortcut; it is a burden of accountability. "Empowerment is amazing, right? It gives you this wide variety of ways you can move, but it also holds you very accountable for what you’re doing."
Implications for the Industry
The path carved by FUJIFILM Biotechnologies under Pedersen’s operational leadership offers a blueprint for the next decade of biopharma. The implications are clear:
- Standardization as a Competitive Moat: The kojoX model suggests that the future of CDMO dominance lies in "networked manufacturing," where a drug process is not localized to one site, but is portable across a global infrastructure.
- Regulatory-First AI: The successful scaling of AI in pharma will not come from external software vendors alone, but from companies that build internal, secure, and validated AI ecosystems (like GenkiBot) that align with GMP requirements.
- The End of the "Command and Control" Era: As bioprocessing becomes more data-dense and complex, the traditional hierarchical decision-making model is becoming a liability. Pedersen’s focus on the "9 People Fundamentals" suggests that the most successful companies will be those that invest as heavily in organizational psychology as they do in bioreactor capacity.
As the industry looks toward 2030, the ability to balance the rigid requirements of regulatory compliance with the fluid, rapid potential of AI and human autonomy will define which players lead the market. For Maja Herold Pedersen and FUJIFILM Biotechnologies, the goal is simple: to make the science of manufacturing as agile as the science of medicine itself.
About the Author
